Lyell Immunopharma, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-47.9M | $-57.6M | $9.7M | $22.0M |
| Jun 2022 | $-44.3M | $-51.5M | $7.2M | — |
| Sep 2022 | $-37.1M | $-39.9M | $2.8M | — |
| Mar 2023 | $-46.2M | $-47.7M | $1.5M | $13.9M |
| Jun 2023 | $-39.2M | $-40.1M | $933.0K | — |
| Sep 2023 | $-37.7M | $-37.9M | $195.0K | — |
| Mar 2024 | $-42.0M | $-42.0M | $30.0K | $9.2M |
| Jun 2024 | $-38.1M | $-38.4M | $331.0K | — |
| Sep 2024 | $-35.0M | $-35.1M | $59.0K | — |
| Mar 2025 | $-54.7M | $-55.0M | $246.0K | $6.0M |
| Jun 2025 | $-34.5M | $-34.6M | $168.0K | — |
| Sep 2025 | $-28.6M | $-28.6M | $62.0K | — |
| Mar 2026 | $-38.5M | $-38.6M | $89.0K | $4.3M |
| Jun 2026 | $-33.9M | $-34.2M | $256.0K | — |